Douglas Fleming

Background

About Douglas Fleming

Physician and epidemiologist, clinical trialist and expert in Drug Safety. Doug received his BA in humanities and physics from Yale, and served as a Peace Corps Volunteer teacher in Kenya. He earned an MD from Yale Medical School, and did his residency in Internal Medicine at Mount Auburn Hospital of Harvard Medical School. He did his fellowship in Epidemiology with the Epidemic Intelligence Service of the United States Centers for Disease Control (CDC) in Atlanta, Georgia. Doug worked in public health for 15 years, teaching internal medicine at an inner-city health center, and later serving in CDC’s Global AIDS Program in Botswana (southern Africa), running clinical trials for HIV and TB medications. When he returned to the United States in 2007, he joined Bristol-Myers Squibb, where he worked for 5 years on clinical development in diabetes, and he developed epidemiologic tools for safety analyses. He joined Lexicon Pharmaceuticals in 2013 as Medical Lead for telotristat etiprate, and for 3 years led development of this new drug for a particular rare cancer (carcinoid tumor). The drug aims to reduce the severe effects of this tumor on the heart muscle. The drug’s clinical trials were successful, and were published in the Journal of Clinical Oncology. The drug subsequently was approved by FDA and EMA. In 2016, he returned to Bristol-Myers Squibb, where he led a group of physicians and epidemiologists who designed and built advanced epidemiological and clinical tools to detect and understand potential safety signals. In September 2020, he began a new role at BMS as Executive Director, Immunology & Fibrosis & CV, with Medical Capabilities / Medical Data Generation